Ragnhild Adelheid Lothe

• Langerud, Jonas; Eilertsen, Ina Andrassy; Moosavi, Hossein; Klokkerud, Solveig Margrete Knoph; Reims, Henrik Mikael & Backe, Ingeborg Flåten [Vis alle 13 forfattere av denne artikkelen] (2024). Multiregional transcriptomics identifies congruent consensus subtypes with prognostic value beyond tumor heterogeneity of colorectal cancer. Nature Communications. ISSN 2041-1723. 15(1). doi: 10.1038/s41467-024-48706-2.
• Totland, Max; Knudsen, Lars Mørland; Rasmussen, Nikoline Lander; Omori, Yasufumi; Sørensen, Vigdis & Elster, Vilde Cecilie Wivestad [Vis alle 17 forfattere av denne artikkelen] (2024). The E3 ubiquitin ligase ITCH negatively regulates intercellular communication via gap junctions by targeting connexin43 for lysosomal degradation. Cellular and Molecular Life Sciences (CMLS). ISSN 1420-682X. 81(1). doi: 10.1007/s00018-024-05165-8.
• Majid, Umair; Bergsland, Christian Holst; Sveen, Anita; Bruun, Jarle; Eilertsen, Ina Andrassy & Bækkevold, Espen Sønderaal [Vis alle 10 forfattere av denne artikkelen] (2024). The prognostic effect of tumor-associated macrophages in stage I-III colorectal cancer depends on T cell infiltration. Cellular Oncology. ISSN 2211-3428. doi: 10.1007/s13402-024-00926-w.
• Sveen, Anita; Johannessen, Bjarne; Klokkerud, Solveig M.K.; Kraggerud, Sigrid M.; Meza, Leonardo Zepeda & Bjørnslett, Merete Pauline [Vis alle 13 forfattere av denne artikkelen] (2024). Evolutionary mode and timing of dissemination of high-grade serous carcinomas. JCI Insight. ISSN 2379-3708. 9(3). doi: 10.1172/jci.insight.170423.
• Høland, Maren; Berg, Kaja Christine Graue; Eilertsen, Ina Andrassy; Bjerkehagen, Bodil; Kolberg, Matthias & Pedersen, Kjetil Boye [Vis alle 16 forfattere av denne artikkelen] (2023). Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets. EBioMedicine. ISSN 2352-3964. 97:104829, s. 1–17. doi: 10.1016/j.ebiom.2023.104829. Fulltekst i vitenarkiv
• Bogaard, Mari; Skotheim, Rolf I.; Maltau, Aase Margrethe Victoria; Kidd, Susanne Gundersen; Lothe, Ragnhild Adelheid & Axcrona, Karol [Vis alle 7 forfattere av denne artikkelen] (2023). "High proliferative cribriform prostate cancer" defines a patient subgroup with an inferior prognosis. Histopathology. ISSN 0309-0167. 83(6), s. 853–869. doi: 10.1111/his.15012. Fulltekst i vitenarkiv
• Grasso, Chiara; Popovic, Maja; Isaevska, Elena; Lazzarato, Fulvio; Fiano, Valentina & Zugna, Daniela [Vis alle 47 forfattere av denne artikkelen] (2022). Association Study between Polymorphisms in DNA Methylation-Related Genes and Testicular Germ Cell Tumor Risk. Cancer Epidemiology, Biomarkers and Prevention. ISSN 1055-9965. 31(9), s. 1769–1779. doi: 10.1158/1055-9965.EPI-22-0123.
• Carm, Kristina Totland; Johannessen, Bjarne; Bogaard, Mari; Bakken, Anne Cathrine; Maltau, Aase Margrethe Victoria & Hoff, Andreas Midbøe [Vis alle 10 forfattere av denne artikkelen] (2022). Somatic mutations reveal complex metastatic seeding from multifocal primary prostate cancer. International Journal of Cancer. ISSN 0020-7136. 152(5), s. 945–951. doi: 10.1002/ijc.34226. Fulltekst i vitenarkiv
• Kidd, Susanne Gundersen; Bogaard, Mari; Carm, Kristina Totland; Bakken, Anne Cathrine; Maltau, Aase Margrethe Victoria & Løvf, Marthe [Vis alle 10 forfattere av denne artikkelen] (2022). In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis. Molecular Oncology. ISSN 1574-7891. 16(15), s. 2810–2822. doi: 10.1002/1878-0261.13225. Fulltekst i vitenarkiv
• Strømme, Jonas Meier; Johannessen, Bjarne; Kidd, Susanne Gundersen; Bogaard, Mari; Carm, Kristina Totland & Zhang, Xiaokang [Vis alle 12 forfattere av denne artikkelen] (2022). Expressed prognostic biomarkers for primary prostate cancer independent of multifocality and transcriptome heterogeneity. Cancer Gene Therapy. ISSN 0929-1903. 29(8-9), s. 1276–1284. doi: 10.1038/s41417-022-00444-7. Vis sammendrag

  The majority of prostate cancer patients are diagnosed with multiple primary malignant foci. The distinct foci are exceptionally heterogeneous with regard to DNA mutations, but whether this is recapitulated at the transcriptome level remains unknown. In this study, inter- and intrafocal heterogeneity has been assessed by whole-transcriptome sequencing of 87 tissue samples from 23 patients with localized prostate cancer treated with radical prostatectomy. From each patient, multiple samples were taken from one or more malignant foci, in addition to one sample from benign prostate tissue. Transcriptomic profiles of different malignant foci from the same patient showed a similar level of heterogeneity as tumors from different patients. This applies to expression of genes, fusion genes, and somatic mutations. Within-patient pair-wise analyses identified expression patterns linked to ETS status and extraprostatic extension. A set of 62 genes were found with low intrapatient heterogeneity and high interpatient heterogeneity, retaining stable expression profiles across foci within the same patient. Among these, 16 genes are associated with biochemical recurrence in a separately published study and are therefore nominated as biomarkers with prognostic value regardless of which malignant focus is sampled. In conclusion, an extensive heterogeneity in multifocal prostate cancer is confirmed at the gene expression level. Diagnostic biomarkers were identified for ETS positive samples and samples from extraprostatic extensions. Finally, prognostic biomarkers independent of multifocal heterogeneity were found.

• Bergsland, Christian Holst; Jeanmougin, Marine; Moosavi, Seyed Hossein; Svindland, Aud; Bruun, Jarle & Nesbakken, Arild [Vis alle 8 forfattere av denne artikkelen] (2022). Spatial analysis and CD25-expression identify regulatory T cells as predictors of a poor prognosis in colorectal cancer. Modern Pathology. ISSN 0893-3952. 35, s. 1236–1246. doi: 10.1038/s41379-022-01086-8. Fulltekst i vitenarkiv
• Aasebø, Kristine Øverås; Bruun, Jarle; Bergsland, Christian Holst; Nunes, Luis; Eide, Geir Egil & Pfeiffer, Per [Vis alle 10 forfattere av denne artikkelen] (2022). Prognostic role of tumour infiltrating lymphocytes and macrophages in relation to tumour MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients. British Journal of Cancer. ISSN 0007-0920. 126(1), s. 48–56. doi: 10.1038/s41416-021-01586-5.
• Pluta, John; Pyle, Louise C.; Nead, Kevin T.; Wilf, Rona; Li, Mingyao & Mitra, Nandita [Vis alle 57 forfattere av denne artikkelen] (2021). Identification of 22 susceptibility loci associated with testicular germ cell tumors. Nature Communications. ISSN 2041-1723. 12(1), s. 1–13. doi: 10.1038/s41467-021-24334-y.
• Sveen, Anita; Johannessen, Bjarne; Eilertsen, Ina Andrassy; Røsok, Bård Ingvald; Gulla, Marie & Eide, Peter Andreas Wold [Vis alle 14 forfattere av denne artikkelen] (2021). The expressed mutational landscape of microsatellite stable colorectal cancers. Genome Medicine. ISSN 1756-994X. 13. doi: 10.1186/s13073-021-00955-2. Fulltekst i vitenarkiv
• Bruun, Jarle; Eide, Peter Andreas Wold; Bergsland, Christian Holst; Brück, Oscar; Svindland, Aud & Arjama, Mariliina [Vis alle 13 forfattere av denne artikkelen] (2021). E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models. Molecular Oncology. ISSN 1574-7891. 00, s. 1–18. doi: 10.1002/1878-0261.13159. Fulltekst i vitenarkiv
• Moosavi, Seyed Hossein; Eide, Peter Andreas Wold; Eilertsen, Ina Andrassy; Brunsell, Tuva Høst; Berg, Kaja Christine Graue & Røsok, Bård Ingvald [Vis alle 12 forfattere av denne artikkelen] (2021). De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity. Genome Medicine. ISSN 1756-994X. 13, s. 143–143. doi: 10.1186/s13073-021-00956-1. Fulltekst i vitenarkiv
• Slørdahl, Kathinka; Klotz, Dagmar; Olsen, Jan Åge; Skovlund, Eva; Undseth, Christine & Abildgaard, Heidi L. [Vis alle 17 forfattere av denne artikkelen] (2021). Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer. Acta Oncologica. ISSN 0284-186X. 60(7), s. 921–930. doi: 10.1080/0284186X.2021.1918763. Fulltekst i vitenarkiv
• Eide, Peter Andreas Wold; Moosavi, Seyed Hossein; Eilertsen, Ina Andrassy; Brunsell, Tuva Høst; Langerud, Jonas & Berg, Kaja Christine Graue [Vis alle 11 forfattere av denne artikkelen] (2021). Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer. NPJ GENOMIC MEDICINE. ISSN 2056-7944. 6:59, s. 1–9. doi: 10.1038/s41525-021-00223-7. Fulltekst i vitenarkiv
• Kryeziu, Kushtrim; Moosavi, Seyed Hossein; Bergsland, Christian Holst; Guren, Marianne; Eide, Peter Andreas Wold & Totland, Max [Vis alle 11 forfattere av denne artikkelen] (2021). Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases. Journal of Translational Medicine. ISSN 1479-5876. 19:384, s. 1–11. doi: 10.1186/s12967-021-03062-3. Fulltekst i vitenarkiv
• Kidd, Susanne Gundersen; Carm, Kristina Totland; Bogaard, Mari; Olsen, Linn Guro; Bakken, Anne Cathrine & Løvf, Marthe [Vis alle 10 forfattere av denne artikkelen] (2021). High expression of SCHLAP1 in primary prostate cancer is an independent predictor of biochemical recurrence, despite substantial heterogeneity. Neoplasia. ISSN 1522-8002. 23(6), s. 634–641. doi: 10.1016/j.neo.2021.05.012. Fulltekst i vitenarkiv Vis sammendrag

  In primary prostate cancer, the common multifocality and heterogeneity are major obstacles in finding robust prognostic tissue biomarkers. The long noncoding RNA SCHLAP1 has been suggested, but its prognostic value has not been investigated in the context of tumor heterogeneity. In the present study, expression of SCHLAP1 was investigated using real-time RT-PCR in a multisampled series of 778 tissue samples from radical prostatectomies of 164 prostate cancer patients (median follow-up time 7.4 y). The prognostic value of SCHLAP1 was evaluated with biochemical recurrence as endpoint. In total, 29% of patients were classified as having high expression of SCHLAP1 in at least one malignant sample. Among these, inter- and intrafocal heterogeneity was detected in 72% and 56%, respectively. High expression of SCHLAP1 was shown to be a predictor of biochemical recurrence in both uni- and multivariable cox regression analyses ( P < 0.001 and P = 0.02). High expression of SCHLAP1 was also significantly associated with adverse clinicopathological characteristics, including grade group, high pT stage, invasive cribriform growth/intraductal carcinoma of the prostate, and reactive stroma. In conclusion, high expression of SCHLAP1 in at least one malignant sample is a robust prognostic biomarker in primary prostate cancer. For the first time, high SCHLAP1 expression has been associated with the aggressive histopathologic feature reactive stroma. The expression of SCHLAP1 is highly heterogeneous, and analysis of multiple samples is therefore crucial in determination of the SCHLAP1 status of a patient.

• Bruun, Jarle; Kryeziu, Kushtrim; Eide, Peter Andreas Wold; Moosavi, Seyed Hossein; Eilertsen, Ina Andrassy & Røsok, Bård Ingvald [Vis alle 21 forfattere av denne artikkelen] (2020). Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity. Clinical Cancer Research. ISSN 1078-0432. 26(15), s. 4107–4119. doi: 10.1158/1078-0432.CCR-19-3637. Vis sammendrag

  Abstract Purpose: Molecular tumor heterogeneity may have important implications for the efficacy of targeted therapies in metastatic cancers. Inter-metastatic heterogeneity of sensitivity to anticancer agents has not been well explored in colorectal cancer. Experimental Design: We established a platform for ex vivo pharmacogenomic profiling of patient-derived organoids (PDO) from resected colorectal cancer liver metastases. Drug sensitivity testing (n = 40 clinically relevant agents) and gene expression profiling were performed on 39 metastases from 22 patients. Results: Three drug–response clusters were identified among the colorectal cancer metastases, based primarily on sensitivities to EGFR and/or MDM2 inhibition, and corresponding with RAS mutations and TP53 activity. Potentially effective therapies, including off-label use of drugs approved for other cancer types, could be nominated for eighteen patients (82%). Antimetabolites and targeted agents lacking a decisive genomic marker had stronger differential activity than most approved chemotherapies. We found limited intra-patient drug sensitivity heterogeneity between PDOs from multiple (2–5) liver metastases from each of ten patients. This was recapitulated at the gene expression level, with a highly proportional degree of transcriptomic and pharmacological variation. One PDO with a multi-drug resistance profile, including resistance to EGFR inhibition in a RAS-mutant background, showed sensitivity to MEK plus mTOR/AKT inhibition, corresponding with low-level PTEN expression. Conclusions: Intra-patient inter-metastatic pharmacological heterogeneity was not pronounced and ex vivo drug screening may identify novel treatment options for metastatic colorectal cancer. Variation in drug sensitivities was reflected at the transcriptomic level, suggesting potential to develop gene expression–based predictive signatures to guide experimental therapies.

• Wise, Jillian; Nakken, Sigve; Steen, Chloe Beate; Vodak, Daniel; Trøen, Gunhild & Johannessen, Bjarne [Vis alle 24 forfattere av denne artikkelen] (2020). Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series. Blood Advances. ISSN 2473-9529. 4(9), s. 1859–1866. doi: 10.1182/bloodadvances.2019001325. Vis sammendrag

  • Diagnostic and relapse diffuse large B-cell lymphoma (DLBCL) biopsies reveal increased mutational burden/loss of heterozygosity in HLA-A. • Serially sampled tumor biopsies provide insight into therapeutic targets and evolutionary divergence in relapsed/refractory DLBCL.

• da Costa Florim Ribeiro Lopes, Nair Susana; Bergsland, Christian Holst; Bruun, Jarle; Bjørnslett, Merete Pauline; Vieira, André Filipe & Mesquita, Patrícia [Vis alle 14 forfattere av denne artikkelen] (2020). A panel of intestinal differentiation markers (CDX2, GPA33, and LI-cadherin) identifies gastric cancer patients with favourable prognosis. Gastric Cancer. ISSN 1436-3291. 23(5), s. 811–823. doi: 10.1007/s10120-020-01064-6.
• Smeby, Jørgen; Kryeziu, Kushtrim; Berg, Kaja Christine Graue; Eilertsen, Ina Andrassy; Eide, Peter Andreas Wold & Johannessen, Bjarne [Vis alle 11 forfattere av denne artikkelen] (2020). Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. EBioMedicine. ISSN 2352-3964. 59:102923, s. 1–13. doi: 10.1016/j.ebiom.2020.102923. Fulltekst i vitenarkiv
• Hoff, Andreas Midbøe; Kraggerud, Sigrid M.; Alagaratnam, Sharmini; Berg, Kaja Christine Graue; Johannessen, Bjarne & Høland, Maren [Vis alle 11 forfattere av denne artikkelen] (2020). Frequent copy number gains of SLC2A3 and ETV1 in testicular embryonal carcinomas. Endocrine-Related Cancer. ISSN 1351-0088. 27(9), s. 457–468. doi: 10.1530/ERC-20-0064. Fulltekst i vitenarkiv
• Berg, Kaja Christine Graue; Brunsell, Tuva Høst; Sveen, Anita; Alagaratnam, Sharmini; Bjørnslett, Merete Pauline & Hektoen, Merete [Vis alle 11 forfattere av denne artikkelen] (2020). Genomic and prognostic heterogeneity among RAS/BRAFV600E/TP53 co-mutated resectable colorectal liver metastases. Molecular Oncology. ISSN 1574-7891. s. 1–16. doi: 10.1002/1878-0261.12885. Fulltekst i vitenarkiv
• Bergsland, Christian Holst; Bruun, Jarle; Guren, Marianne; Svindland, Aud; Bjørnslett, Merete Pauline & Smeby, Jørgen [Vis alle 16 forfattere av denne artikkelen] (2020). Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer. ESMO Open. ISSN 2059-7029. 5:e001040(6), s. 1–12. doi: 10.1136/esmoopen-2020-001040. Fulltekst i vitenarkiv
• Flatin, Bjørnar Tovson Bae; Vedeld, Hege Marie; Pinto, Rita; Langerud, Jonas; Lind, Guro Elisabeth & Lothe, Ragnhild A [Vis alle 8 forfattere av denne artikkelen] (2020). Multiregional assessment of CIMP in primary colorectal cancers: Phenotype concordance but marker variability. International Journal of Cancer. ISSN 0020-7136. s. 1–6. doi: 10.1002/ijc.33425. Fulltekst i vitenarkiv
• Jeanmougin, Marine; Håvik, Annette Bentsen; Cekaite, Lina; Brandal, Petter; Sveen, Anita & Meling, Torstein Ragnar [Vis alle 11 forfattere av denne artikkelen] (2020). Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment. Molecular Oncology. ISSN 1574-7891. s. 1016–1027. doi: 10.1002/1878-0261.12668. Fulltekst i vitenarkiv
• Eilertsen, Ina Andrassy; Moosavi, Seyed Hossein; Strømme, Jonas Meier; Nesbakken, Arild; Johannessen, Bjarne & Lothe, Ragnhild A [Vis alle 7 forfattere av denne artikkelen] (2019). Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer. Cancer Letters. ISSN 0304-3835. 469, s. 246–255. doi: 10.1016/j.canlet.2019.10.040. Fulltekst i vitenarkiv
• Brunsell, Tuva Høst; Sveen, Anita; Bjørnbeth, Bjørn Atle; Røsok, Bård Ingvald; Danielsen, Stine Aske & Brudvik, Kristoffer Watten [Vis alle 13 forfattere av denne artikkelen] (2019). High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases. Clinical colorectal cancer. ISSN 1533-0028. 19(1), s. 26–47. doi: 10.1016/j.clcc.2019.09.003. Fulltekst i vitenarkiv
• Burocziova, Monika; Burdova, Kamila; Martinikova, Andra S.; Kasparek, Petr; Kleiblova, Petra & Danielsen, Stine Aske [Vis alle 24 forfattere av denne artikkelen] (2019). Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon. Cell Death & Disease. ISSN 2041-4889. 10:818(11), s. 1–15. doi: 10.1038/s41419-019-2057-4.
• da Costa Florim Ribeiro Lopes, Nair Susana; Bergsland, Christian Holst; Bjørnslett, Merete Pauline; Pellinen, Teijo Severi; Svindland, Aud & Nesbakken, Arild [Vis alle 10 forfattere av denne artikkelen] (2019). Digital image analysis of multiplex fluorescence IHC in colorectal cancer recognizes the prognostic value of CDX2 and its negative correlation with SOX2. Laboratory Investigation. ISSN 0023-6837. 100(1), s. 120–134. doi: 10.1038/s41374-019-0336-4. Fulltekst i vitenarkiv
• Dienstmann, Rodrigo; Villacampa, Guillermo; Sveen, Anita; Mason, Michael J.; Niedzwiecki, Donna & Nesbakken, Arild [Vis alle 10 forfattere av denne artikkelen] (2019). Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. Annals of Oncology. ISSN 0923-7534. 30(10), s. 1622–1629. doi: 10.1093/annonc/mdz287. Fulltekst i vitenarkiv
• Carm, Kristina Totland; Hoff, Andreas Midbøe; Bakken, Anne Cathrine; Axcrona, Ulrika; Axcrona, Karol & Lothe, Ragnhild A [Vis alle 8 forfattere av denne artikkelen] (2019). Interfocal heterogeneity challenges the clinical usefulness of molecular classification of primary prostate cancer. Scientific Reports. ISSN 2045-2322. 9(1). doi: 10.1038/s41598-019-49964-7. Fulltekst i vitenarkiv Vis sammendrag

  Prostate cancer is a highly heterogeneous disease and typically multiple distinct cancer foci are present at primary diagnosis. Molecular classification of prostate cancer can potentially aid the precision of diagnosis and treatment. A promising genomic classifier was published by The Cancer Genome Atlas (TCGA), successfully classifying 74% of primary prostate cancers into seven groups based on one cancer sample per patient. Here, we explore the clinical usefulness of this classification by testing the classifier's performance in a multifocal context. We analyzed 106 cancer samples from 85 distinct cancer foci within 39 patients. By somatic mutation data from whole-exome sequencing and targeted qualitative and quantitative gene expression assays, 31% of the patients were uniquely classified into one of the seven TCGA classes. Further, different samples from the same focus had conflicting classification in 12% of the foci. In conclusion, the level of both intra- and interfocal heterogeneity is extensive and must be taken into consideration in the development of clinically useful molecular classification of primary prostate cancer.

• Glaire, Mark A; Domingo, Enric; Sveen, Anita; Bruun, Jarle; Nesbakken, Arild & Nicholson, George [Vis alle 16 forfattere av denne artikkelen] (2019). Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage. British Journal of Cancer. ISSN 0007-0920. 121, s. 474–482. doi: 10.1038/s41416-019-0540-4. Fulltekst i vitenarkiv
• Smeby, Jørgen; Sveen, Anita; Bergsland, Christian Holst; Eilertsen, Ina Andrassy; Danielsen, Stine Aske & Eide, Peter Andreas Wold [Vis alle 11 forfattere av denne artikkelen] (2019). Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer. ESMO Open. ISSN 2059-7029. 4:e000523(3), s. 1–10. doi: 10.1136/esmoopen-2019-000523. Fulltekst i vitenarkiv
• Brunsell, Tuva Høst; Cengija, Vanja; Sveen, Anita; Bjørnbeth, Bjørn Atle; Røsok, Bård Ingvald & Brudvik, Kristoffer Watten [Vis alle 10 forfattere av denne artikkelen] (2019). Heterogeneous radiological response to neoadjuvant therapy is associated with poor prognosis after resection of colorectal liver metastases. European Journal of Surgical Oncology. ISSN 0748-7983. s. 1–7. doi: 10.1016/j.ejso.2019.07.017. Fulltekst i vitenarkiv
• Berg, Kaja Christine Graue; Sveen, Anita; Høland, Maren; Alagaratnam, Sharmini; Rasmussen, Marianne Berg & Danielsen, Stine Aske [Vis alle 9 forfattere av denne artikkelen] (2019). Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains. Oncogene. ISSN 0950-9232. 38(33), s. 6109–6122. doi: 10.1038/s41388-019-0868-5. Fulltekst i vitenarkiv
• Sveen, Anita; Kopetz, Scott & Lothe, Ragnhild A (2019). Biomarker-guided therapy for colorectal cancer: strength in complexity. Nature Reviews Clinical Oncology. ISSN 1759-4774. s. 1–22. doi: 10.1038/s41571-019-0241-1.
• Smeby, Jørgen; Sveen, Anita; Eilertsen, Ina Andrassy; Danielsen, Stine Aske; Hoff, Andreas Midbøe & Eide, Peter Andreas Wold [Vis alle 12 forfattere av denne artikkelen] (2019). Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer. Oncogenesis. ISSN 2157-9024. 8:35(6), s. 1–8. doi: 10.1038/s41389-019-0141-3. Fulltekst i vitenarkiv
• Røsok, Bård Ingvald; Brunsell, Tuva Høst; Brudvik, Kristoffer Watten; Carling, Johan Ulrik; Dorenberg, Eric Jürgen & Björnsson, B. [Vis alle 9 forfattere av denne artikkelen] (2019). Characterization of early recurrences following liver resection by ALPPS and two stage hepatectomy in patients with colorectal liver-metastases and small future liver remnants; a translational substudy of the LIGRO-RCT. HPB. ISSN 1365-182X. 21(8), s. 1017–1023. doi: 10.1016/j.hpb.2018.12.003.
• Eide, Peter Andreas Wold; Eilertsen, Ina Andrassy; Sveen, Anita & Lothe, Ragnhild A (2019). Long noncoding RNA MIR31HG is a bona fide prognostic marker with colorectal cancer cell-intrinsic properties. International Journal of Cancer. ISSN 0020-7136. s. 1–12. doi: 10.1002/ijc.31998. Fulltekst i vitenarkiv
• Kryeziu, Kushtrim; Bruun, Jarle; Guren, Tormod Kyrre; Sveen, Anita & Lothe, Ragnhild A (2019). Combination therapies with HSP90 inhibitors against colorectal cancer. Biochimica et Biophysica Acta. CR. Reviews on Cancer. ISSN 0304-419X. 1871(2), s. 240–247. doi: 10.1016/j.bbcan.2019.01.002. Fulltekst i vitenarkiv
• Pinto, Diana; Pinto, Carla; Guerra, Joana; Pinheiro, Manuela; Santos, Rui & Vedeld, Hege Marie [Vis alle 15 forfattere av denne artikkelen] (2018). Contribution of MLH1 constitutional methylation for Lynch syndrome diagnosis in patients with tumor MLH1 downregulation. Cancer Medicine. ISSN 2045-7634. 7(2), s. 433–444. doi: 10.1002/cam4.1285. Vis sammendrag

  Constitutional epimutation of the two major mismatch repair genes, MLH1 and MSH2, has been identified as an alternative mechanism that predisposes to the development of Lynch syndrome. In the present work, we aimed to investigate the prevalence of MLH1 constitutional methylation in colorectal cancer (CRC) patients with abnormal expression of the MLH1 protein in their tumors. In a series of 38 patients who met clinical criteria for Lynch syndrome genetic testing, with loss of MLH1 expression in the tumor and with no germline mutations in the MLH1 gene (35/38) or with tumors presenting the BRAF p.Val600Glu mutation (3/38), we screened for constitutional methylation of the MLH1 gene promoter using methylation‐specific multiplex ligation‐dependent probe amplification (MS‐MLPA) in various biological samples. We found four (4/38; 10.5%) patients with constitutional methylation in the MLH1 gene promoter. RNA studies demonstrated decreased MLH1 expression in the cases with constitutional methylation when compared with controls. We could infer the mosaic nature of MLH1 constitutional hypermethylation in tissues originated from different embryonic germ layers, and in one family we could show that it occurred de novo. We conclude that constitutional MLH1 methylation occurs in a significant proportion of patients who have loss of MLH1 protein expression in their tumors and no MLH1 pathogenic germline mutation. Furthermore, we provide evidence that MLH1 constitutional hypermethylation is the molecular mechanism behind about 3% of Lynch syndrome families diagnosed in our institution, especially in patients with early onset or multiple primary tumors without significant family history.

• Eilertsen, Ina Andrassy; Sveen, Anita; Strømme, Jonas Meier; Skotheim, Rolf I.; Nesbakken, Arild & Lothe, Ragnhild A (2018). Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer . International Journal of Cancer. ISSN 0020-7136. 144(4), s. 841–847. doi: 10.1002/ijc.31809. Fulltekst i vitenarkiv Vis sammendrag

  KRAS mutation is a well‐known marker for poor response to targeted treatment and patient prognosis in microsatellite stable (MSS) colorectal cancer (CRC). However, variation in clinical outcomes among patients wild‐type for KRAS underlines that this is not a homogeneous population. Here, we evaluated the prognostic impact of KRAS alternative splicing in relation to mutation status in a single‐hospital series of primary MSS CRCs (N = 258). Using splicing‐sensitive microarrays and RNA sequencing, the relative expression of KRAS‐4A versus KRAS‐4B transcript variants was confirmed to be down‐regulated in CRC compared to normal colonic mucosa (N = 41; p ≤ 0.001). This was independent of mutation status, however, gene set enrichment analysis revealed that the effect of splicing on KRAS signaling was specific to the KRAS wild‐type subgroup, in which low relative KRAS‐4A expression was associated with a higher level of KRAS signaling (p = 0.005). In concordance, the prognostic value of KRAS splicing was also dependent on mutation status, and for patients with Stage I–III KRAS wild‐type MSS CRC, low relative KRAS‐4A expression was associated with inferior overall survival (HR: 2.36, 95% CI: 1.07–5.18, p = 0.033), a result not found in mutant cases (pinteraction = 0.026). The prognostic association in the wild‐type subgroup was independent of clinicopathological factors, including cancer stage in multivariable analysis (HR: 2.68, 95% CI: 1.18–6.09, p = 0.018). This suggests that KRAS has prognostic value beyond mutation status in MSS CRC, and highlights the importance of molecular heterogeneity in the clinically relevant KRAS wild‐type subgroup.

• Bruun, Jarle; Sveen, Anita; Barros, Rita; Eide, Peter Andreas Wold; Eilertsen, Ina Andrassy & Kolberg, Matthias [Vis alle 14 forfattere av denne artikkelen] (2018). Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer. Molecular Oncology. ISSN 1574-7891. 12(9), s. 1639–1655. doi: 10.1002/1878-0261.12347. Fulltekst i vitenarkiv
• Løvf, Marthe; Zhao, Sen; Axcrona, Ulrika; Johannessen, Bjarne; Bakken, Anne Cathrine & Carm, Kristina Totland [Vis alle 13 forfattere av denne artikkelen] (2018). Multifocal primary prostate cancer exhibits high degree of genomic heterogeneity. European Urology. ISSN 0302-2838. s. 1–8. doi: 10.1016/j.eururo.2018.08.009.
• Høland, Maren; Kolberg, Matthias; Danielsen, Stine Aske; Bjerkehagen, Bodil; Eilertsen, Ina Andrassy & Hektoen, Merete [Vis alle 14 forfattere av denne artikkelen] (2018). Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53. Modern Pathology. ISSN 0893-3952. s. 1–14. doi: 10.1038/s41379-018-0074-y. Fulltekst i vitenarkiv
• Smeby, Jørgen; Sveen, Anita; Merok, Marianne Aarstad; Danielsen, Stine Aske; Eilertsen, Ina Andrassy & Guren, Marianne [Vis alle 9 forfattere av denne artikkelen] (2018). CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. Annals of Oncology. ISSN 0923-7534. 29(5), s. 1227–1234. doi: 10.1093/annonc/mdy085. Fulltekst i vitenarkiv
• Pharo, Heidi Dietrichson; Andresen, Kim; Berg, Kaja Christine Graue; Lothe, Ragnhild A; Jeanmougin, Marine & Lind, Guro Elisabeth (2018). A robust internal control for high-precision DNA methylation analyses by droplet digital PCR. Clinical Epigenetics. ISSN 1868-7075. 10(24). doi: 10.1186/s13148-018-0456-5. Fulltekst i vitenarkiv
• Vedeld, Hege Marie; Nesbakken, Arild; Lothe, Ragnhild A & Lind, Guro Elisabeth (2018). Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer. Clinical Epigenetics. ISSN 1868-7075. 10(1). doi: 10.1186/s13148-018-0503-2.
• Oltedal, Satu; Kørner, Hartwig; Aasprong, Ole Gunnar; Hussain, Israr; Tjensvoll, Kjersti & Smaaland, Rune [Vis alle 12 forfattere av denne artikkelen] (2018). The Prognostic Relevance of Sentinel Lymph Node Metastases Assessed by PHGR1 mRNA Quantification in Stage I to III Colon Cancer. Translational Oncology. ISSN 1944-7124. 11(2), s. 436–443. doi: 10.1016/j.tranon.2018.01.015.
• Danielsen, Håvard Emil; Hveem, Tarjei Sveinsgjerd; Domingo, Enric; Pradhan, Manohar; Kleppe, Andreas & Syvertsen, Rolf Anders [Vis alle 18 forfattere av denne artikkelen] (2018). Prognostic markers for colorectal cancer: Estimating ploidy and stroma. Annals of Oncology. ISSN 0923-7534. 29(3), s. 616–623. doi: 10.1093/annonc/mdx794.
• Eide, Peter Andreas Wold; Bruun, Jarle; Lothe, Ragnhild A & Sveen, Anita (2017). CMScaller: An R package for consensus molecular subtyping of colorectal cancer pre-clinical models. Scientific Reports. ISSN 2045-2322. 7(1). doi: 10.1038/s41598-017-16747-x. Vis sammendrag

  Colorectal cancers (CRCs) can be divided into four gene expression-based biologically distinct consensus molecular subtypes (CMS). This classification provides a potential framework for stratified treatment, but to identify novel CMS-drug associations, translation of the subtypes to pre-clinical models is essential. The currently available classifier is dependent on gene expression signals from the immune and stromal compartments of tumors and fails to identify the poor-prognostic CMS4-mesenchymal group in immortalized cell lines, patient-derived organoids and xenografts. To address this, we present a novel CMS classifier based on a filtered set of cancer cell-intrinsic, subtype-enriched gene expression markers. This new classifier, referred to as CMScaller, recapitulated the subtypes in both in vitro and in vivo models (551 in total). Importantly, by analyzing public drug response data from patient-derived xenografts and cell lines, we show that the subtypes are predictive of response to standard CRC drugs. CMScaller is available as an R package.

• Sveen, Anita; Bruun, Jarle; Eide, Peter Andreas Wold; Eilertsen, Ina Andrassy; Ramirez, Lorena & Murumagi, Astrid [Vis alle 17 forfattere av denne artikkelen] (2017). Colorectal cancer consensus molecular subtypes translated to preclinical models uncover potentially targetable cancer cell dependencies. Clinical Cancer Research. ISSN 1078-0432. 24(4), s. 794–806. doi: 10.1158/1078-0432.CCR-17-1234.
• Dienstmann, Rodrigo; Mason, M; Sinicrope, FA; Phipps, Alison; Tejpar, S. & Nesbakken, Arild [Vis alle 14 forfattere av denne artikkelen] (2017). Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Annals of Oncology. ISSN 0923-7534. 28(5), s. 1023–1031. doi: 10.1093/annonc/mdx052. Fulltekst i vitenarkiv
• Kolberg, Matthias; Bruun, Jarle; Murumagi, Astrid; Mpindi, John P.; Bergsland, Christian Holst & Høland, Maren [Vis alle 10 forfattere av denne artikkelen] (2017). Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors. Molecular Oncology. ISSN 1574-7891. 11(9), s. 1156–1171. doi: 10.1002/1878-0261.12086.
• Totland, Max; Bergsland, Christian Holst; Fykerud, Tone Aase; Knudsen, Lars Mørland; Rasmussen, Nikoline L. & Eide, Peter Andreas Wold [Vis alle 11 forfattere av denne artikkelen] (2017). The E3 ubiquitin ligase NEDD4 induces endocytosis and lysosomal sorting of connexin 43 to promote loss of gap junctions. Journal of Cell Science. ISSN 0021-9533. 130(17), s. 2867–2882. doi: 10.1242/jcs.202408.
• Lind, Guro Elisabeth; Guriby, Marianne; Ahlquist, Terje Cruickshank; Hussain, Israr; Jeanmougin, Marine & Søreide, Kjetil [Vis alle 9 forfattere av denne artikkelen] (2017). Prognostic relevance of an epigenetic biomarker panel in sentinel lymph nodes from colon cancer patients. Clinical Epigenetics. ISSN 1868-7075. 9:97, s. 1–8. doi: 10.1186/s13148-017-0397-4. Fulltekst i vitenarkiv
• Vedeld, Hege Marie; Merok, Marianne Aarstad; Jeanmougin, Marine; Danielsen, Stine Aske; Honne, Hilde & Presthus, Gro [Vis alle 13 forfattere av denne artikkelen] (2017). CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers. International Journal of Cancer. ISSN 0020-7136. 141(5), s. 967–976. doi: 10.1002/ijc.30796.
• Landskron, Johannes; Kraggerud, Sigrid M.; Wik, Elisabeth; Dørum, Anne; Bjørnslett, Merete Pauline & Melum, Espen [Vis alle 11 forfattere av denne artikkelen] (2017). C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease. PLOS ONE. ISSN 1932-6203. 12:e0182030(7), s. 1–12. doi: 10.1371/journal.pone.0182030. Fulltekst i vitenarkiv
• Sveen, Anita; Bruun, Jarle; Eide, Peter W.; Eilertsen, Ina A.; Ramirez, Lorena & Murumagi, Astrid [Vis alle 17 forfattere av denne artikkelen] (2017). Colorectal cancer consensus molecular subtypes define selective activity of HSP90 inhibitors in preclinical models. Cancer Reports and Reviews. ISSN 2513-9290. doi: 10.1158/1078-0432.CCR-17-1234.
• Berg, Kaja Christine Graue; Eide, Peter Andreas Wold; Eilertsen, Ina Andrassy; Johannessen, Bjarne; Bruun, Jarle & Danielsen, Stine Aske [Vis alle 14 forfattere av denne artikkelen] (2017). Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies. Molecular Cancer. ISSN 1476-4598. 16:116, s. 1–16. doi: 10.1186/s12943-017-0691-y.
• Sveen, Anita; Johannessen, Bjarne; Tengs, Torstein; Danielsen, Stine Aske; Eilertsen, Ina Andrassy & Lind, Guro Elisabeth [Vis alle 16 forfattere av denne artikkelen] (2017). Multilevel genomics of colorectal cancers with microsatellite instability – clinical impact of JAK1 mutations and consensus molecular subtype 1. Genome Medicine. ISSN 1756-994X. 9(1). doi: 10.1186/s13073-017-0434-0.
• Ramalho-Carvalho, João; Martins, João Barbosa; Cekaite, Lina; Sveen, Anita; Torres-Ferreira, Jorge & Graça, Inês [Vis alle 13 forfattere av denne artikkelen] (2017). Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1. Cancer Letters. ISSN 0304-3835. 385, s. 150–159. doi: 10.1016/j.canlet.2016.10.028.
• Glaire, M.A.; Domingo, E.; Vermeulen, L.; van Wezel, T; Liefers, G.J. & Lothe, Ragnhild Adelheid [Vis alle 20 forfattere av denne artikkelen] (2016). POLE proofreading domain mutation defines a subset of immunogenic colorectal cancers with excellent prognosis. Annals of Oncology. ISSN 0923-7534. 27. doi: 10.1093/annonc/mdw370.09.
• Domingo, Enric; Freeman-Mills, Luke; Rayner, Emily; Glaire, Mark; Briggs, Sarah & Vermeulen, Louis [Vis alle 35 forfattere av denne artikkelen] (2016). Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. The Lancet Gastroenterology and Hepatology. ISSN 2468-1253. 1(3), s. 207–216. doi: 10.1016/S2468-1253(16)30014-0.
• Fykerud, Tone Aase; Knudsen, Lars Mørland; Totland, Max; Sørensen, Vigdis; Dahal-Koirala, Shiva & Lothe, Ragnhild A [Vis alle 8 forfattere av denne artikkelen] (2016). Mitotic cells form actin-based bridges with adjacent cells to provide intercellular communication during rounding. Cell Cycle. ISSN 1538-4101. 15(21), s. 2943–2957. doi: 10.1080/15384101.2016.1231280. Fulltekst i vitenarkiv
• Sveen, Anita; Løes, Inger Marie; Alagaratnam, Sharmini; Nilsen, Gro; Høland, Maren & Lingjærde, Ole Christian [Vis alle 13 forfattere av denne artikkelen] (2016). Intra-patient inter-metastatic genetic heterogeneity in colorectal cancer as a key determinant of survival after curative liver resection. PLoS Genetics. ISSN 1553-7390. 12:e1006225(7). doi: 10.1371/journal.pgen.1006225.
• Sveen, Anita; Kilpinen, Sami; Ruusulehto, Anja; Lothe, Ragnhild A & Skotheim, Rolf Inge (2016). Aberrant RNA splicing in cancer; Expression changes and driver mutations of splicing factor genes. Oncogene. ISSN 0950-9232. 35(19), s. 2413–2427. doi: 10.1038/onc.2015.318.
• Lorenz, Susanne; Barøy, Tale; Sun, Jinchang; Nome, Torfinn; Vodak, Daniel & Bryne, Jan Christian [Vis alle 21 forfattere av denne artikkelen] (2016). Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations. OncoTarget. ISSN 1949-2553. 7(5), s. 5273–5288. doi: 10.18632/oncotarget.6567. Vis sammendrag

  In contrast to many other sarcoma subtypes, the chaotic karyotypes of osteosarcoma have precluded the identification of pathognomonic translocations. We here report hundreds of genomic rearrangements in osteosarcoma cell lines, showing clear characteristics of microhomology-mediated break-induced replication (MMBIR) and end-joining repair (MMEJ) mechanisms. However, at RNA level, the majority of the fused transcripts did not correspond to genomic rearrangements, suggesting the involvement of trans-splicing, which was further supported by typical trans-splicing characteristics. By combining genomic and transcriptomic analysis, certain recurrent rearrangements were identified and further validated in patient biopsies, including a PMP22-ELOVL5 gene fusion, genomic structural variations affecting RB1, MTAP/CDKN2A and MDM2, and, most frequently, rearrangements involving TP53. Most cell lines (7/11) and a large fraction of tumor samples (10/25) showed TP53 rearrangements, in addition to somatic point mutations (6 patient samples, 1 cell line) and MDM2 amplifications (2 patient samples, 2 cell lines). The resulting inactivation of p53 was demonstrated by a deficiency of the radiation-induced DNA damage response. Thus, TP53 rearrangements are the major mechanism of p53 inactivation in osteosarcoma. Together with active MMBIR and MMEJ, this inactivation probably contributes to the exceptional chromosomal instability in these tumors. Although rampant rearrangements appear to be a phenotype of osteosarcomas, we demonstrate that among the huge number of probable passenger rearrangements, specific recurrent, possibly oncogenic, events are present. For the first time the genomic chaos of osteosarcoma is characterized so thoroughly and delivered new insights in mechanisms involved in osteosarcoma development and may contribute to new diagnostic and therapeutic strategies.

• Hoff, Andreas Midbøe; Alagaratnam, Sharmini; Zhao, Sen; Bruun, Jarle; Andrews, PW & Lothe, Ragnhild A [Vis alle 7 forfattere av denne artikkelen] (2016). Identification of novel fusion genes in testicular germ cell tumors. Cancer Research. ISSN 0008-5472. 76(1), s. 108–116. doi: 10.1158/0008-5472.CAN-15-1790.
• Cekaite, Lina; Eide, Peter Andreas Wold; Lind, Guro Elisabeth; Skotheim, Rolf I. & Lothe, Ragnhild A (2015). MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer. OncoTarget. ISSN 1949-2553. 7(6), s. 6476–6505. doi: 10.18632/oncotarget.6390.
• Kolberg, Matthias; Smeland, Sigbjørn & Lothe, Ragnhild A (2015). Adjuvant chemotherapy in malignant peripheral nerve sheath tumors. Chemotherapy: Open Access. ISSN 2167-7700. 4(3). doi: 10.4172/2167-7700.1000158.
• Brabrand, Sigmund; Johannessen, Bjarne; Axcrona, Ulrika; Kraggerud, Sigrid M.; Berg, Kaja Christine Graue & Bakken, Anne Cathrine [Vis alle 11 forfattere av denne artikkelen] (2015). Exome sequencing of bilateral testicular germ cell tumors suggests independent development lineages. Neoplasia. ISSN 1522-8002. 17(2), s. 167–174. doi: 10.1016/j.neo.2014.12.005.
• Bruun, Jarle; Kolberg, Matthias; Ahlquist, Terje Cruickshank; Røyrvik, Ellen Christine; Nome, Torfinn & Leithe, Edward [Vis alle 18 forfattere av denne artikkelen] (2015). Regulator of chromosome condensation 2 identifies high-risk patients within both major phenotypes of colorectal cancer. Clinical Cancer Research. ISSN 1078-0432. 21(16), s. 3759–3770. doi: 10.1158/1078-0432.CCR-14-3294.
• Hoff, Andreas Midbøe; Johannessen, Bjarne; Alagaratnam, Sharmini; Zhao, Sen; Nome, Torfinn & Løvf, Marthe [Vis alle 11 forfattere av denne artikkelen] (2015). Novel RNA variants in colorectal cancers. OncoTarget. ISSN 1949-2553. 6(34), s. 36587–36602. doi: 10.18632/oncotarget.5500.
• Kolberg, Matthias; Høland, Maren; Lind, Guro Elisabeth; Ågesen, Trude Holmeide; Skotheim, Rolf Inge & Hall, Kirsten Sundby [Vis alle 11 forfattere av denne artikkelen] (2015). Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours - A prognostic test after surgical resection. Molecular Oncology. ISSN 1574-7891. 9(6), s. 1129–1139. doi: 10.1016/j.molonc.2015.02.005.
• Sirnes, Solveig; Lind, Guro Elisabeth; Bruun, Jarle; Fykerud, Tone Aase; Mesnil, Marc & Lothe, Ragnhild A [Vis alle 9 forfattere av denne artikkelen] (2015). Connexins in colorectal cancer pathogenesis. International Journal of Cancer. ISSN 0020-7136. 137(1), s. 1–11. doi: 10.1002/ijc.28911.
• Mesquita, Diana; Barros-Silva, João D.; Santos, Joana; Skotheim, Rolf Inge; Lothe, Ragnhild A & Paulo, Paula [Vis alle 7 forfattere av denne artikkelen] (2015). Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts. OncoTarget. ISSN 1949-2553. 6(7), s. 5217–5236. doi: 10.18632/oncotarget.2847.
• Andresen, Kim; Boberg, Kirsten Muri; Vedeld, Hege Marie; Honne, Hilde; Jebsen, Peter Wilhelm & Hektoen, Merete [Vis alle 16 forfattere av denne artikkelen] (2015). Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinoma. Hepatology. ISSN 0270-9139. 61(5), s. 1651–1659. doi: 10.1002/hep.27707.
• Danielsen, Stine Aske; Eide, Peter Andreas Wold; Nesbakken, Arild; Guren, Tormod Kyrre; Leithe, Edward & Lothe, Ragnhild A (2015). Portrait of the PI3K/AKT pathway in colorectal cancer. Acta Biochimica et Biophysica Sinica. ISSN 0582-9879. 1855(1), s. 104–121. doi: 10.1016/j.bbcan.2014.09.008.
• Danielsen, Stine Aske; Lind, Guro Elisabeth; Kolberg, Matthias; Høland, Maren; Bjerkehagen, Bodil & Hall, Kirsten Sundby [Vis alle 11 forfattere av denne artikkelen] (2015). Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis. Neuro-Oncology. ISSN 1522-8517. 17(1), s. 63–69. doi: 10.1093/neuonc/nou140.
• Almeida, Mafalda; Costa, Vera L; Costa, Natália R.; Ramalho-Carvalho, João; Baptista, Tiago & Ribeiro, Franclim R [Vis alle 13 forfattere av denne artikkelen] (2014). Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential. Journal of Cellular and Molecular Medicine. ISSN 1582-1838. 18(11), s. 2287–2297. doi: 10.1111/jcmm.12394.
• Hveem, Tarjei Sveinsgjerd; Merok, Marianne Aarstad; Pretorius, Maria; Novelli, Marco; Silihagen, Mette & Sjo, Ole Helmer [Vis alle 12 forfattere av denne artikkelen] (2014). Prognostic impact of genomic instability in colorectal cancer. British Journal of Cancer. ISSN 0007-0920. 110(8), s. 2159–2164. doi: 10.1038/bjc.2014.133.
• Bethge, Nicole; Lothe, Ragnhild A; Honne, Hilde; Andresen, Kim; Trøen, Gunhild & Eknæs, Mette [Vis alle 11 forfattere av denne artikkelen] (2014). Colorectal cancer DNA methylation marker panel validated with high performance in Non-Hodgkin lymphoma. Epigenetics. ISSN 1559-2294. 9(3), s. 428–436. doi: 10.4161/epi.27554.
• Vedeld, Hege Marie; Skotheim, Rolf Inge; Lothe, Ragnhild A & Lind, Guro Elisabeth (2014). The recently suggested intestinal cancer stem cell marker DCLK1 is an epigenetic biomarker for colorectal cancer. Epigenetics. ISSN 1559-2294. 9(3), s. 346–350. doi: 10.4161/epi.27582.
• Sveen, Anita; Johannessen, Bjarne; Teixeira, Manuel; Lothe, Ragnhild A & Skotheim, Rolf Inge (2014). Transcriptome instability as a molecular pan-cancer characteristic of carcinomas. BMC Genomics. ISSN 1471-2164. 15(1). doi: 10.1186/1471-2164-15-672.

Se alle arbeider i Cristin

• Tasken, Kjetil; Russnes, Hege Elisabeth Giercksky; Aas, Eline; Bjørge, Line; Blix, Egil Støre & Ahlquist, Terje C. [Vis alle 116 forfattere av denne artikkelen] (2022). A national precision cancer medicine implementation initiative for Norway. Nature Medicine. ISSN 1078-8956. 28(5), s. 885–887. doi: 10.1038/s41591-022-01777-4.
• Helland, Åslaug; Russnes, Hege Elisabeth Giercksky; Fagereng, Gro Live; Al-Shibli, Khalid Ibrahim; Andersson, Yvonne & Berg, Thomas [Vis alle 53 forfattere av denne artikkelen] (2022). Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway (Journal of Translational Medicine, (2022), 20, 1, (225), 10.1186/s12967-022-03432-5). Journal of Translational Medicine. ISSN 1479-5876. 20(1). doi: 10.1186/s12967-022-03518-0.
• Helland, Åslaug; Russnes, Hege Elisabeth Giercksky; Fagereng, Gro Live; Al-Shibli, Khalid Ibrahim; Andersson, Yvonne & Berg, Thomas [Vis alle 53 forfattere av denne artikkelen] (2022). Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway. Journal of Translational Medicine. ISSN 1479-5876. 20(1), s. 1–11. doi: 10.1186/s12967-022-03432-5. Fulltekst i vitenarkiv Vis sammendrag

  Background Matching treatment based on tumour molecular characteristics has revolutionized the treatment of some cancers and has given hope to many patients. Although personalized cancer care is an old concept, renewed attention has arisen due to recent advancements in cancer diagnostics including access to high-throughput sequencing of tumour tissue. Targeted therapies interfering with cancer specific pathways have been developed and approved for subgroups of patients. These drugs might just as well be efficient in other diagnostic subgroups, not investigated in pharma-led clinical studies, but their potential use on new indications is never explored due to limited number of patients. Methods In this national, investigator-initiated, prospective, open-label, non-randomized combined basket- and umbrella-trial, patients are enrolled in multiple parallel cohorts. Each cohort is defined by the patient’s tumour type, molecular profile of the tumour, and study drug. Treatment outcome in each cohort is monitored by using a Simon two-stage-like ‘admissible’ monitoring plan to identify evidence of clinical activity. All drugs available in IMPRESS-Norway have regulatory approval and are funded by pharmaceutical companies. Molecular diagnostics are funded by the public health care system.

• Kryeziu, Kushtrim; Bergsland, Christian Holst; Guren, Tormod Kyrre; Sveen, Anita & Lothe, Ragnhild Adelheid (2022). Multiplex immunohistochemistry of metastatic colorectal cancer and ex vivo tumor avatars. Biochimica et Biophysica Acta. CR. Reviews on Cancer. ISSN 0304-419X. 1877(1). doi: 10.1016/j.bbcan.2022.188682.
• Glaire, Mark; Domingo, Enric; Sveen, Anita; Bruun, Jarle; Nesbakken, Arild & Nicholson, George [Vis alle 16 forfattere av denne artikkelen] (2019). Correction: Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage (British Journal of Cancer, (2019), 121, 6, (474-482), 10.1038/s41416-019-0540-4). British Journal of Cancer. ISSN 0007-0920. 121(9). doi: 10.1038/s41416-019-0590-7.
• Bruun, Jarle; Eide, Peter W.; Kryeziu, Kushtrim; Sveen, Anita; Murumagi, Astrid & Kolberg, Matthias [Vis alle 9 forfattere av denne artikkelen] (2017). Pharmacogenomic profiling to identify novel therapeutic strategies in colorectal cancer.
• Oltedal, Satu; Kørner, Hartwig; Aasprong, Ole Gunnar; Hussain, Israr; Tjensvoll, Kjersti & Smaaland, Rune [Vis alle 12 forfattere av denne artikkelen] (2017). The Prognostic Relevance of Sentinel Lymph Node Metastases Assessed by PHGR1 mRNA Quantitation in Stage I-III Colon Cancer.
• Jeanmougin, M; Håvik, Annette Bentsen; Cekaite, Lina; Brandal, Petter; Sveen, Anders & Meling, Torstein Ragnar [Vis alle 11 forfattere av denne artikkelen] (2016). Primary and secondary glioblastomas: global expression analysis of two histologically indistinguishable tumor subtypes.
• Myklebost, Ola; Lothe, Ragnhild A; Gjertsen, Bjørn Tore & Lønning, Per Eystein (2015). Bør hver kreftpasient bli et eget forskningsprosjekt? Aftenposten (morgenutg. : trykt utg.). ISSN 0804-3116.
• Håvik, Annette Bentsen; Lind, Guro Elisabeth; Honne, Hilde; Meling, Torstein; Scheie, David & Hall, Kirsten Sundby [Vis alle 12 forfattere av denne artikkelen] (2014). Sequencing IDH1/2 glioma mutation hotspots in gliomas and malignant peripheral nerve sheath tumors. Neuro-Oncology. ISSN 1522-8517. 16(2), s. 320–322. doi: 10.1093/neuonc/not230.
• Høland, Maren; Kolberg, Mathias; Davidson, Ben; Sundby Hall, Kirsten; Mertens, Fredrik & van den Berg, E [Vis alle 10 forfattere av denne artikkelen] (2014). Genomic copy number changes and the prognostic impact of the encoded genes PTEN and BIRC5 in malignant peripheral nerve sheath tumours. European Journal of Cancer. ISSN 0959-8049. 50, s. 106–106.

Se alle arbeider i Cristin